PPT-Elbasvir-Grazoprevir

Sofosbuvir in TreatmentNaïve HCV Genotype 1 or 3 CSWIFT Phase 2 Treatment Naïve Poordad F et al EASL 2015 Abstract O006 Source Poordad F et al EASL 2015 Abstract . Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. C-WORTHY Study Part C: . grazoprevir. . + . elbasvir. ± RBV in genotype 1b. GZR + EBR + RBV. N = 30. N = 31. Design. W8. C-WORTHY/C. Vierling. . JM. EASL 2015, . Abs. . P0769 . >. 18 years. HCV genotype 1b. grazoprevir. . + . elbasvir. . in genotype 1 with Child-Pugh B cirrhosis. Jacobson IM. . EASL 2015, Abs. O008. Design. Child-Pugh B. GZR . 100 mg + . EBR . 50 mg. GZR 50 mg + EBR 50 mg. Non-cirrhotic. D : . grazoprevir. . + . elbasvir. + RBV in genotype 3. C-WORTHY/D. Gane. . E. EASL 2015, Abs. . P0776. GZR + EBR + RBV. GZR + EBR + RBV. N = 21. N = 20. Design. W12. W18. SVR. 12. >. 18 years. . +/- Ribavirin in HCV Genotype 1, 4 or 6. C-EDGE Treatment Experienced (TE). Phase 3. . Treatment. . Experienced. Kwo. P, . et al. . EASL 2015. Abstract P0886.. Source: . Kwo. P et al. EASL 2015. Abstract P0886.. + . Grazoprevir. in . GT 1 . and Chronic Renal Disease. C. -SURFER. Phase 3. Treatment. Naïve and Treatment . Experienced. Roth D, . et al. Lancet . 2015;386:1537-45.. Source: Roth . D, et al. Lancet 2015;386:1537-45.. X. J . Hepatology. 2015; 63: 564-72. C-SALVAGE Study: . grazoprevir. . + . elbasvir. + RBV in genotype 1 with failure to PI-based regimen. NS3 and NS5A RAVs identified by population sequencing at baseline and VF. in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. Ribavirin in PI-experienced HCV GT1. C-SALVAGE. Phase . 2 . Treatment. . Experienced. (1) . Buti. M, et al. . Clin. Infect Dis. 2016;62:32-6. (2) . Forns. X, et al. J . Hepatol. . 2015;63:564-72. C-EDGE Treatment Naïve (TN). Phase 3. . Treatment. . Naïve. Zeuzem. S, . et al. . Ann Intern Med. 2015;163:1-13.. Source: . Zeuzem. S, et al. Ann Intern Med. 2015;163:1-13. .. Elbasvir-Grazoprevir. University of Chicago. Chicago, Illinois. Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection. FORMATTED: 05/02/2016. Chicago, Illinois: May 9, 2016. From . AI . Aronsohn. C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N = 21. N = 20. Design. W12. W18. SVR. 12. >. 18 years. HCV genotype . 3. HCV RNA ≥ 10 000 IU/mL. Treatment naïve . No cirrhosis. No HBV or HIV co-infection. HCV . GT 1,4, or 6 in PWID* on Opiate Agonist Therapy. C-EDGE CO-STAR. Phase . 2. Treatment. . Naïve. Dore G, . et al. . AALSD. 2015; Abstract 40. . Injection Drug Use. *PWID = Persons . W. ho . I. Kristen M. Marks, MD. Assistant Professor. Weill Cornell Medical College . New York, New York. Financial Relationships With Commercial Entities. Dr Marks was awarded research grants, paid to her institution, from Bristol-Myers Squibb, Gilead Sciences, .